Axcella Health Inc. (AXLA)
Dec 29, 2023 - AXLA was delisted (reason: company dissolved)
0.401
0.00 (0.00%)
Last trade price
Company Description
Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States.
The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence.
The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016.
Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
Axcella Health Inc.
| Country | MA |
| Founded | 2008 |
| IPO Date | May 9, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Craig R. Jalbert CIRA |
Contact Details
Address: 840 Memorial Drive, Third Floor Cambridge, Massachusetts 02139 United States | |
| Phone | 617-868-0949 |
| Website | axcellahealth.com |
Stock Details
| Ticker Symbol | AXLA |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001633070 |
| CUSIP Number | 05454B105 |
| ISIN Number | US05454B2043 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| William R. Hinshaw Jr. | President, Chief Executive Officer and Director |
| Dr. Alison D. Schecter M.D. | President of Strategy and Operations |
| David R. Epstein B.Sc., M.B.A. | Consultant |
| Laurent Chardonnet | Consultant |
| Robert W. Crane | Senior Vice President and Chief Financial Officer |
| Dr. Paul Fehlner J.D., Ph.D. | Senior Vice President, Chief Legal Officer and Corporate Secretary |
| Virginia R. Dean | Senior Vice President and Chief People Officer |
| Dr. Larry Bell | Global Head of Regulatory Affairs and Pharmacovigilance and Senior Vice President |
| Dr. Margaret James Koziel M.D. | Senior Vice President and Chief Medical Officer |
| Dan Kirby | Senior Vice President of Strategic Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 22, 2023 | 8-K | Current Report |
| Dec 19, 2023 | 8-K | Current Report |
| Dec 4, 2023 | 8-K | Current Report |
| Nov 17, 2023 | 8-K | Current Report |
| Nov 17, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Nov 17, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Nov 17, 2023 | DEF 14A | Other definitive proxy statements |
| Nov 9, 2023 | 8-K | Current Report |
| Nov 6, 2023 | PRE 14A | Other preliminary proxy statements |
| Nov 1, 2023 | 8-K | Current Report |